ER+ breast tumors are targeted using selective estrogen receptor modulators (SERMs), aromatase inhibitors, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, and ER degraders also called selective estrogen receptor downregulators (SERDs) (13). This evidence concerns the gene CDK4 and breast neoplasm.